Free Newsletter
SPOTLIGHT: Thailand skirts Plavix patent
Thailand's health ministry has decided to import a generic version of the heart drug Plavix from India, even though the Schering Plough drug is still under patent. Made by M-Cure, the pills will be imported using compulsory licensing, a World Trade Organization waiver that allows developing nations to bypass drug patents when they have no means to pay for branded versions of necessary drugs. Previously, the Thai government had invoked compulsory licensing for two anti-HIV agents. E.U. and U.S. officials protested the Plavix decision. Report
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline


SHARE
WITH: